По материалам обновленных рекомендаций Европейской антиревматической лиги (EULAR) по лечению системной красной волчанки – 2019: дискуссионные вопросы и комментарии

Многообразие клинических проявлений системной красной  волчанки  (СКВ),  волнообразное течение с чередованием ремиссий  и обострений  делают это заболевание одним из наиболее трудных для диагностики, лечения и оценки  эффективности терапии.

Несмотря  на то что разработанные в последние  годы методы ранней диагностики, способы применения комбинированной патогенетической терапии и мониторинга течения болезни привели  к увеличению  выживаемости (≥90%) и продолжительности жизни пациентов с СКВ, остается еще много нерешенных проблем. В частности, эффективность лечения СКВ пока не достаточна и полностью  контролировать активность  заболевания удается нечасто. Рецидивирующее течение СКВ в сочетании  с коморбидной патологией, а также неблагоприятным воздействием  глюкокортикоидов (ГК) и иммуносупрессантов способствует накоплению необратимых  органных повреждений.

Статья посвящена обзору обновленных рекомендаций Европейской антиревматической лиги (EULAR)  по лечению СКВ, которые были опубликованы в 2019 г. Представлены комментарии и дискуссионные вопросы с учетом российских  рекомендаций по лечению СКВ.

1. Насонов ЕЛ, редактор. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. С. 429-8.

2. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533

3. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139

4. Mosca M, Boumpas D, Bruce IN, et al. Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol. 2012;30(suppl.73): S112-115.

5. Клюквина НГ. Алгоритм лечения системной красной волчанки. Современное состояние проблемы. Медицинский совет. 2016;(8):99-105 doi: 10.21518/2079-701X-2016-8

6. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task Force of the EULAR standing Committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67(2):195-205. doi: 10.1136/ard.2007.070367

7. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi: 10.1136/ard.2010.130476

8. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European Renal Association-European dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940

9. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-85. doi: 10.1136/annrheumdis-2016-209770

10. Mosca M, Tani C, Aringer M, et al. European League against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74. doi: 10.1136/ard.2009.117200

11. Boumpas DT, Bertsias GK, Fanouriakis A. 2008–2018: a decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis. 2018;77(11):1547-8. doi: 10.1136/annrheumdis-2018-214014

12. Попкова ТВ, Лисицына ТА. Рекомендации по ведению больных системной красной волчанкой в клинической практике (по материалам рекомендаций Европейской антиревматической лиги – EULAR). Современная ревматология. 2011;5(1):4-12 doi: 10.14412/1996-7012-2011-645

13. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089

14. Van der Heijde D, Aletaha D, Carmona L. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8-13. doi: 10.1136/annrheumdis-2014-206350

15. Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519

16. Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Рекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16 doi: 10.14412/1995-4484-2015-9-16

17. Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, et al. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016;68(7):981-7. doi: 10.1002/acr.22774

18. Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808-16. doi: 10.3899/jrheum.131137

19. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis. 2017;76(12):2071-4. doi: 10.1136/annrheumdis-2017-211814

20. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467-72.

21. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347

22. Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(1):121-8. doi: 10.1093/rheumatology/kew377

23. Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis. 2018;77(1):104-10. doi: 10.1136/annrheumdis-2017-211613

24. Polachek A, Gladman DD, Su J, et al. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(7):997-1003. doi: 10.1002/acr.23109

25. Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):822-8. doi: 10.1002/acr.23720

26. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of longterm renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheum. 2015;67(5):1305-13. doi: 10.1002/art.39026

27. Touma Z, Urowitz MB, Ibanez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014;41(4):688-97. doi: 10.3899/jrheum.130005

28. Mackay M, Dall'Era M, Fishbein J, et al. Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheum. 2019;71(3):411-9. doi: 10.1002/art.40724

29. Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20(5):453-62. doi: 10.1177/0961203310388445

30. Koutsonikoli A, Trachana M, Heidich A-B, et al. Dissecting the damage in northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int. 2015;35(7):1225-32. doi: 10.1007/s00296-014-3209-6

31. Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015;74(6):1019-23. doi: 10.1136/annrheumdis-2013-204620

32. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726

33. Kasitanon N, Intaniwet T, Wangkaew S, et al. The clinically quiescent phase in early diagnosed SLE patients: inception cohort study. Rheumatology. 2015;54(5):868-75. doi: 10.1093/rheumatology/keu406

34. Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken). 2012;64(4):511-8. doi: 10.1002/acr.21568

35. Соловьев СК, Асеева ЕА, Зоткин ЕГ и др. Проблемы низкой активности и ремиссии при системной красной волчанке. Научно-практическая ревматология. 2019;57(2):218-21 doi: 10.14412/1995-4484-2019-218-221

36. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8. doi: 10.1136/ard.2008.101766

37. Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821-4. doi: 10.1136/ard.2006.067835

38. Iudici M, Pantano I, Fasano S, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018;27(2):265-72. doi: 10.1177/0961203317717631

39. Mok CC, Penn HJ, Chan KL, et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken). 2016;68(9):1295-302. doi: 10.1002/acr.22837

40. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459

41. Kim J-W, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017;44(11):1674-9. doi: 10.3899/jrheum.170158

42. Food and Drug Administration. Guidance for Industry-Systemic Lupus Erythematosus-Developing Medical Products for Treatment. Available from: http://google2.fda.gov/search?q=lupus+trials&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive:Yes&output=xml_no_dtd&getfields=* (accessed 10 March 2014).

43. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1426-39. doi: 10.3899/jrheum.171459

44. Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171

45. Chen H-L, Shen L-J, Hsu P-N, et al. Cumulative burden of Glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83-89. doi: 10.3899/jrheum.160214

46. Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenileonset systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 2017;69(11):1627-35. doi: 10.1002/acr.23199

47. Yee C-S, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836-43. doi: 10.1093/rheumatology/keu412

48. Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus – the Hopkins Lupus Cohort. Lupus Sci Med. 2015 Mar;2(1):e000066. doi: 10.1136/lupus-2014-000066. eCollection 2015.

49. Ruiz-Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14(10):875-9. doi: 10.1016/j.autrev.2015.05.011

50. Thamer MAE, Hernan MA, Zhang YI, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36(3):560-4. doi: 10.3899/jrheum.080828

51. Buttgereit F, da Silva JAP, Boers M, et al. Standardised Nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-22. doi: 10.1136/ard.61.8.718

52. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res (Hoboken). 2018;70(4):582-91. doi: 10.1002/acr.23322

53. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-32. doi: 10.1016/j.autrev.2017.05.017

54. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145-53. doi: 10.1093/rheumatology/ker410

55. Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775-85. doi: 10.1002/acr.22035

56. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014; 23:225-35.

57. Tselios K, Gladman DD, Su J, et al. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016;43(3):552-8. doi: 10.3899/jrheum.150779

58. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69-78. doi: 10.3899/jrheum.100130

59. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-82. doi: 10.1136/annrheumdis-2016-210882

60. Knight JH, Howards PP, Spencer JB, et al. Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the goal study. Lupus Sci Med. 2016;3(1):e000139. Collection 2016.

61. Mok CC, Chan PT, To CH. Anti-Mü llerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65(1):206-10. doi: 10.1002/art.37719

62. Tamirou F, Husson SN, Gruson D, et al. Brief report: The Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of antimü llerian hormone. Arthritis Rheum. 2017;69(6):1267-71. doi: 10.1002/art.40079

63. Blumenfeld Z, Mischari O, Schultz N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum. 2011;41(3):346-52. doi: 10.1016/j.semarthrit.2011.05.008

64. Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. doi: 10.3109/09513590.2011.650752

65. Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099

66. Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620-8. doi: 10.1093/rheumatology/kew457

67. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44(2):175-85. doi: 10.1016/j.semarthrit.2014.04.002

68. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359

69. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30. doi: 10.1002/art.30613

70. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet. 2011;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2

71. Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018; 86:1-8. doi: 10.1016/j.jaut.2017.09.004

72. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831

73. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937

74. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009

75. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and metaanalysis. Lupus. 2013;22(14):1489-503. doi: 10.1177/0961203313509295

76. Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of offlabel use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449-56.

77. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-76. doi: 10.1177/0961203309106174

78. Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966-72. doi: 10.1177/0961203315578764

79. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541

80. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol. 2015;2(2):75-81. doi: 10.1016/S2352-3026(15)00003-4

81. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24(7):2157-60. doi: 10.1093/ndt/gfp002

82. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118

83. Kuhn A, Aberer E, Bata-Csö rgö Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389-404. doi: 10.1111/jdv.14053

84. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000; 42:983-7.

85. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: A randomized, vehicle-controlled, doubleblind study. J Am Acad Dermatol. 2011;64(1):37-48. doi: 10.1016/j.jaad.2009.12.053

86. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51(3):407-10. doi: 10.1016/j.jaad.2004.01.044

87. Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54-64,64.e1-2. doi: 10.1016/j.jaad.2010.03.037

88. Costedoat-Chalumeau N, Dunogue B, Leroux G, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317-26. doi: 10.1007/s12016-015-8469-8

89. Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol. 2018;78(1):107-14.e1. doi: 10.1016/j.jaad.2017.08.045

90. Chasset F, Bouaziz J-D, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177(1):188-96. doi: 10.1111/bjd.15312

91. Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18(8):735-9. doi: 10.1177/0961203308101714

92. Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017;153(9):937-9. doi: 10.1001/jamadermatol.2017.1160

93. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarialresistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(4):717-21. e2. doi: 10.1016/j.jaad.2010.08.011

94. Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156(6):1321-7. doi: 10.1111/j.1365-2133.2007. 07826.x

95. Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191

96. Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67(6):1586-91. doi: 10.1002/art.39085

97. Chasset F, Tounsi T, Cesbron E, et al. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(2):342-350.e4. doi: 10.1016/j.jaad.2017.09.059

98. Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616-23. doi: 10.1111/j.1365-2133.2011. 10693.x

99. Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for Attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi: 10.1093/rheumatology/keu384

100. The American College of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F

101. Bortoluzzi A, Fanouriakis A, Appenzeller S, et al. Validity of the Italian algorithm for the Attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open. 2017;7(5): e015546. doi: 10.1136/bmjopen-2016-015546

102. Magro-Checa C, Zirkzee EJ, Beaart-van de Voorde LJJ, et al. Value of multidisciplinary reassessment in Attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from The Leiden NPSLE cohort. Rheumatology (Oxford). 2017;56(10):1676-83. doi: 10.1093/rheumatology/kex019

103. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6(6):358-67. doi: 10.1038/nrrheum.2010.62

104. Bortoluzzi A, Padovan M, Farina I, et al. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo. 2012;64(6):350-9. doi: 10.4081/reumatismo.2012.350

105. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142-50. doi: 10.1212/WNL.0000000000000570

106. Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016;25(6):627-36. doi: 10.1177/0961203315622821

107. Gupta N, Ganpati A, Mandal S, et al. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017;36(10):2273-9. doi: 10.1007/s10067-017-3775-6

108. Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41(3):364-72. doi: 10.1016/j.semarthrit.2011.06.004

109. Pamfil C, Fanouriakis A, Damian L, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482. Epub 2015 Jan 30.

110. Jung J-H, Soh M-S, Ahn Y-H, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore). 2016;95(6): e2818. doi: 10.1097/MD.0000000000002818

111. Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93(3):424-9. doi: 10.1002/ajh.24999

112. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172-82. doi: 10.1182/blood-2017-09-742353

113. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg. 2004; 240:286-92. doi: 10.1097/01.sla.0000133182.92780.9c

114. Artim-Esen B, Cene E, Sahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41(7):1304-10. doi: 10.3899/jrheum.130984

115. Duarte-Garcia A, Barr E, Magder LS, et al. Predictors of incident proteinuria among patients with SLE. Lupus Sci Med. 2017;4(1): e000200. doi: 10.1136/lupus-2016-000200

116. Tang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore). 2010;89(1):62-7. doi: 10.1097/MD.0b013e3181cb449c

117. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus nephritis trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46:2121-31. doi: 10.1002/art.10461

118. Rijnink EC, Teng YKO, Wilhelmus S, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-43. doi: 10.2215/CJN.10601016

119. Walsh M, Solomons N, Lisk L, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-5. doi: 10.1053/j.ajkd.2012.11.042

120. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from longterm followup of patients in the Euro-Lupus nephritis trial. Arthritis Rheum. 2004; 50:3934-40. doi: 10.1002/art.20666

121. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-95. doi: 10.1056/NEJMoa1014460

122. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the maintain nephritis trial. Ann Rheum Dis. 2010;69(12):2083-9. doi: 10.1136/ard.2010.131995

123. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44. doi: 10.1053/j.ajkd.2010.08.036

124. Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-40. doi: 10.1177/0961203310389486

125. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol. 2009;19(6):606-15. doi: 10.1007/s10165-009-0218-5

126. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. doi: 10.7326/M14-1030

127. Szeto C-C, Kwan BC-H, Lai FM-M, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47(11):1678-81. doi: 10.1093/rheumatology/ken335

128. Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.

129. Панафидина ТА, Попкова ТВ. Общие принципы лечения волчаночного нефрита с профилактикой сердечно-сосудистых осложнений. Современная ревматология. 2018;12(4):4-8 doi: 10.14412/1996-7012-2018-4-4-8

130. Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13(3):281-91. doi: 10.1016/j.autrev.2013.10.014

131. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. doi: 10.1056/NEJMoa1804988

132. Ridker PM. Should aspirin be used for primary prevention in the Post-Statin era? N Engl J Med. 2018;379(16):1572-4. doi: 10.1056/NEJMe1812000

133. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8:237-42. doi: 10.1111/j.1538-7836.2009. 03674.x

134. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132:1365-71. doi: 10.1182/blood-2018-04-848333

135. Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137. doi: 10.1186/s12916-016-0673-8

136. Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38-45. doi: 10.1016/j.semarthrit.2017.01.010

137. Furer V, Rondaan C, Elkayam O, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. doi: 10.1136/annrheumdis-2019-215882

138. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:762-74. doi: 10.1001/jama.2016.0288

139. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41. doi: 10.1177/2047487314546826

140. Wu GC, Leng RX, Lu Q, et al. Subclinical atherosclerosis in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Angiology. 2017 May;68(5):447-61. doi: 10.1177/0003319716652031

141. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity. 2014 Mar;47(2):67-76. doi: 10.3109/08916934.2013.856005

142. Udachkina HV, Novikova DS, Popkova TV, et al. Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months. Rheumatol Int. 2018 Jul;38(7):1217-24. doi: 10.1007/s00296-018-4045-x

143. Udachkina HV, Novikova DS, Popkova TV, et al. Calcification of coronary arteries in early rheumatoid arthritis prior to antirheumatic therapy. Rheumatol Int. 2018 Feb;38(2):211-7. doi: 10.1007/s00296-017-3860-9

144. Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017 Jul;44(7):1032-8. doi: 10.3899/jrheum.161351

145. Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016 Sep;55(9):1623-30. doi: 10.1093/rheumatology/kew231

146. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. doi: 10.1016/S0140-6736(18)31924-X

147. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011 May;70(5):760-5. doi: 10.1136/ard.2010.136762

148. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645

149. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106

150. Панафидина ТА, Попкова ТВ, Алекберова ЗС и др. Значение факторов риска и С-реактивного белка в развитии атеросклероза у женщин с системной красной волчанкой. Клиническая медицина. 2006;84(10):49-54

151. Попкова ТВ, Алекберова ЗС, Александрова ЕН и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Научно-практическая ревматология. 2004;42(4):10-4 doi: 10.14412/1995-4484-2004-795

152. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/S0195-668X (03)00114-3